272 related articles for article (PubMed ID: 19160106)
1. Construction and characterization of a novel superantigen fusion protein: bFGF/SEB.
Wang L; Zhang H; Zhang S; Yu M; Yang X
Cancer Invest; 2009 May; 27(4):376-83. PubMed ID: 19160106
[TBL] [Abstract][Full Text] [Related]
2. Antibody-targeted superantigen therapy induces tumor-infiltrating lymphocytes, excessive cytokine production, and apoptosis in human colon carcinoma.
Litton MJ; Dohlsten M; Lando PA; Kalland T; Ohlsson L; Andersson J; Andersson U
Eur J Immunol; 1996 Jan; 26(1):1-9. PubMed ID: 8566049
[TBL] [Abstract][Full Text] [Related]
3. Superantigen-activated mononuclear cells induce apoptosis in transitional cell carcinoma.
Perabo FG; Willert PL; Wirger A; Schmidt DH; Von Ruecker A; Mueller SC
Anticancer Res; 2005; 25(5):3565-73. PubMed ID: 16101181
[TBL] [Abstract][Full Text] [Related]
4. Differential in vivo effects of a superantigen and an antibody targeted to the same T cell receptor. Activation-induced cell death vs passive macrophage-dependent deletion.
Gonzalo JA; Baixeras E; González-García A; George-Chandy A; Van Rooijen N; Martínez C; Kroemer G
J Immunol; 1994 Feb; 152(4):1597-608. PubMed ID: 8120373
[TBL] [Abstract][Full Text] [Related]
5. Perforin and IFN-gamma are involved in the antitumor effects of antibody-targeted superantigens.
Rosendahl A; Kristensson K; Hansson J; Riesbeck K; Kalland T; Dohlsten M
J Immunol; 1998 Jun; 160(11):5309-13. PubMed ID: 9605129
[TBL] [Abstract][Full Text] [Related]
6. Epicutaneous sensitization with superantigen induces allergic skin inflammation.
Laouini D; Kawamoto S; Yalcindag A; Bryce P; Mizoguchi E; Oettgen H; Geha RS
J Allergy Clin Immunol; 2003 Nov; 112(5):981-7. PubMed ID: 14610492
[TBL] [Abstract][Full Text] [Related]
7. Augmentation of antitumor immunity with bacterial superantigen, staphylococcal enterotoxin B-bound tumor cells.
Shimizu M; Yamamoto A; Nakano H; Matsuzawa A
Cancer Res; 1996 Aug; 56(16):3731-6. PubMed ID: 8706016
[TBL] [Abstract][Full Text] [Related]
8. Persistent production of TH2-type cytokines and polyclonal B cell activation after chronic administration of staphylococcal enterotoxin B in mice.
Florquin S; Amraoui Z; Goldman M
J Autoimmun; 1996 Oct; 9(5):609-15. PubMed ID: 8933276
[TBL] [Abstract][Full Text] [Related]
9. In vivo staphylococcal enterotoxin B (SEB)-primed murine splenocytes secrete mediators which suppress CD25(hi) expression and cell cycle progression of naive splenocytes in response to SEB in vitro.
Hsu LJ; Jan MS; Lin YS
Cell Immunol; 2000 Apr; 201(1):50-7. PubMed ID: 10805973
[TBL] [Abstract][Full Text] [Related]
10. Antitumor response elicited by a superantigen-transmembrane sequence fusion protein anchored onto tumor cells.
Wahlsten JL; Mills CD; Ramakrishnan S
J Immunol; 1998 Dec; 161(12):6761-7. PubMed ID: 9862706
[TBL] [Abstract][Full Text] [Related]
11. Preparation and In Vitro Evaluation of Antitumor Activity of TGFαL3-SEB as a Ligand-Targeted Superantigen.
Yousefi F; Mousavi SF; Siadat SD; Aslani MM; Amani J; Rad HS; Fooladi AA
Technol Cancer Res Treat; 2016 Apr; 15(2):215-26. PubMed ID: 25759426
[TBL] [Abstract][Full Text] [Related]
12. Vbeta-restricted T cell adherence to endothelial cells: a mechanism for superantigen-dependent vascular injury.
Brogan PA; Shah V; Klein N; Dillon MJ
Arthritis Rheum; 2004 Feb; 50(2):589-97. PubMed ID: 14872503
[TBL] [Abstract][Full Text] [Related]
13. The conventional CD4+ T cell response to staphylococcal enterotoxin B is modified by its superantigenic activity.
Wen R; Surman S; Blackman MA; Woodland DL
Cell Immunol; 1997 Mar; 176(2):166-72. PubMed ID: 9073390
[TBL] [Abstract][Full Text] [Related]
14. T-cell immunotherapy for human MK-1-expressing tumors using a fusion protein of the superantigen SEA and anti-MK-1 scFv antibody.
Ueno A; Arakawa F; Abe H; Matsumoto H; Kudo T; Asano R; Tsumoto K; Kumagai I; Kuroki M; Kuroki M
Anticancer Res; 2002; 22(2A):769-76. PubMed ID: 12014649
[TBL] [Abstract][Full Text] [Related]
15. Tumor therapy with an antibody-targeted superantigen generates a dichotomy between local and systemic immune responses.
Litton MJ; Dohlsten M; Hansson J; Rosendahl A; Ohlsson L; Kalland T; Andersson J; Andersson U
Am J Pathol; 1997 May; 150(5):1607-18. PubMed ID: 9137087
[TBL] [Abstract][Full Text] [Related]
16. In vivo analysis of a superantigen-induced T cell suppressor factor.
Hu HL; Cornwell WD; Rogers TJ; Lin YS
Cell Immunol; 1996 Feb; 167(2):285-92. PubMed ID: 8603438
[TBL] [Abstract][Full Text] [Related]
17. Depletion of activated Vbeta8+ T cells disrupts bispecific antibody directed antitumor immunity.
McConnell EJ; McLemore EC; Talac R; Joshi L; Nelson H
J Surg Res; 2004 Nov; 122(1):103-12. PubMed ID: 15522322
[TBL] [Abstract][Full Text] [Related]
18. Natural killer T cells are required for the development of a superantigen-driven T helper type 2 immune response in mice.
Nomizo A; Postol E; de Alencar R; Cardillo F; Mengel J
Immunology; 2005 Oct; 116(2):233-44. PubMed ID: 16162272
[TBL] [Abstract][Full Text] [Related]
19. Staphylococcal enterotoxin B induces hepatic injury and lethal shock in endotoxin-resistant C3H/HeJ mice despite a deficient macrophage response.
Yasuda S; Nagaki M; Moriwaki H
J Endotoxin Res; 2002; 8(4):253-61. PubMed ID: 12230915
[TBL] [Abstract][Full Text] [Related]
20. Tigecycline attenuates staphylococcal superantigen-induced T-cell proliferation and production of cytokines and chemokines.
Saliba R; Paasch L; El Solh A
Immunopharmacol Immunotoxicol; 2009; 31(4):583-8. PubMed ID: 19874226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
